- Home
- ALLE vs SNN Comparison
ALLE vs SNN Comparison
Compare ALLE & SNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ALLE | SNN |
|---|---|---|
| Founded | 2013 | 1856 |
| Country | Ireland | United Kingdom |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Industrial Specialties |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7B | 12.3B |
| IPO Year | 2013 | 2002 |
Fundamental Metrics
Financial Performance| Metric | ALLE | SNN |
|---|---|---|
| Price | $153.11 | $27.46 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 2 |
| Target Price | ★ $167.13 | $36.25 |
| AVG Volume (30 Days) | 1.3M | ★ 1.7M |
| Earning Date | 04-28-2026 | 03-16-2026 |
| Dividend Yield | 1.60% | ★ 2.48% |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 3.74 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.47 | $8.58 |
| Revenue Next Year | $4.58 | $5.60 |
| P/E Ratio | ★ $40.57 | $64.97 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $125.00 | $27.56 |
| 52 Week High | $183.11 | $38.44 |
Technical Indicators
Market Signals| Indicator | ALLE | SNN |
|---|---|---|
| Relative Strength Index (RSI) | 39.02 | 31.53 |
| Support Level | $139.95 | N/A |
| Resistance Level | $166.86 | $31.36 |
| Average True Range (ATR) | 3.46 | 0.53 |
| MACD | -1.43 | -0.13 |
| Stochastic Oscillator | 2.05 | 0.92 |
Price Performance
Historical ComparisonAbout ALLE Allegion plc
Allegion is a global security products company with a portfolio of leading brands such as Schlage, Von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2024, Allegion generated over 75% of sales in the United States. The company primarily competes with Sweden-based Assa Abloy, Switzerland-based Dormakaba, and US-based Fortune Brands Innovations.
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 40% of the UK-based firm's revenue comes from orthopedic products, and another 31% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the US, just over 30% is from other developed markets, and emerging markets account for the remainder.